Literature DB >> 8683726

Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.

W J Kim1, Y Kakehi, H Kinoshita, S Arao, M Fukumoto, O Yoshida.   

Abstract

PURPOSE: Expression levels of the multidrug-resistance (mdr1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in normal kidney and renal cell carcinomas were analyzed to study the complexity of the roles of these genes.
MATERIALS AND METHODS: The reverse transcription-polymerase chain reaction (RT-PCR) assay was used with beta 2 microglobulin (beta 2 m) as the internal control.
RESULTS: In normal kidneys, the expression levels of the 4 genes in individual normal kidney samples correlated significantly with one another. Comparisons of the expression levels between normal kidneys and renal cell carcinomas showed that only the mean MRP gene expression level was higher in renal cell carcinomas than in normal kidneys (p = 0.018). The expression patterns of the 4 genes in renal cell carcinomas differed markedly for nonpapillary and papillary tumors. The mean MRP/beta 2 m ratio for the papillary type was significantly lower than that for the nonpapillary alveolar type carcinoma (p = 0.004). The 4 genes showed moderate positive correlations with one another in alveolar type renal carcinoma similar to the correlations observed in normal kidneys. In contrast, in papillary type, MRP expression was inversely correlated with mdr1 and Topo II expression.
CONCLUSION: Differences in cytogenetic changes, origins and natural histories between papillary and nonpapillary carcinoma may be associated with these distinct expression patterns of the resistance-related genes. Further study is required to clarify whether the differences in the expression patterns between these 2 structural types of carcinoma affect their chemosensitivities and clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683726     DOI: 10.1097/00005392-199608000-00072

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

2.  Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.

Authors:  R G del Moral; M Andujar; C Ramírez; M Gómez-Morales; M Masseroli; M Aguilar; A Olmo; F Arrebola; M Guillén; M J García-Chicano; F F Nogales; F O'Valle
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.

Authors:  S Tanaka; H Kamitani; M R Amin; T Watanabe; H Oka; K Fujii; T Nagashima; T Hori
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

4.  Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients.

Authors:  Yuichi Uwai; Satohiro Masuda; Maki Goto; Hideyuki Motohashi; Hideyuki Saito; Masahiro Okuda; Eijirou Nakamura; Noriyuki Ito; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

5.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

6.  Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.

Authors:  S Hirata; O Katoh; T Oguri; H Watanabe; K Yajin
Journal:  Jpn J Cancer Res       Date:  2000-01

7.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.